Menu
Search
|

Menu

Close
X

Biocept Inc BIOC.OQ (NASDAQ Stock Exchange Capital Market)

1.01 USD
-- (--)
As of Feb 19
chart
Previous Close 1.01
Open --
Volume --
3m Avg Volume 316,388
Today’s High --
Today’s Low --
52 Week High 12.27
52 Week Low 0.66
Shares Outstanding (mil) 12.06
Market Capitalization (mil) 12.18
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 2 analysts

KEY STATS

Revenue (mm, USD)
FY18
2
FY17
5
FY16
3
EPS (USD)
FY18
-7.789
FY17
-21.517
FY16
-65.190
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
36.18
Price to Sales (TTM)
vs sector
3.60
10.03
Price to Book (MRQ)
vs sector
0.44
4.56
Price to Cash Flow (TTM)
vs sector
--
26.61
Total Debt to Equity (MRQ)
vs sector
19.12
16.56
LT Debt to Equity (MRQ)
vs sector
11.37
13.03
Return on Investment (TTM)
vs sector
-280.65
12.67
Return on Equity (TTM)
vs sector
-333.26
13.70

EXECUTIVE LEADERSHIP

David Hale
Non-Executive Chairman of the Board, Since 2014
Salary: $111,289.00
Bonus: --
Michael Nall
President, Chief Executive Officer, Director, Since 2013
Salary: $362,202.00
Bonus: $101,500.00
Timothy Kennedy
Chief Financial Officer and Senior Vice President of Operations, Since 2016
Salary: --
Bonus: --
Lyle Arnold
Senior Vice President - Research & Development, Chief Scientific Officer, Since 2011
Salary: $261,672.00
Bonus: $59,867.00
Edwin Hendrick
Senior Vice President, Chief Commercial Officer, Since 2018
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Medical Equipment, Supplies & Distribution
Address:

5810 Nancy Ridge Dr Ste 150
SAN DIEGO   CA   92121-2840

Phone: +1858.3208200

Biocept, Inc. is an early commercial-stage molecular oncology diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor deoxyribonucleic acid (ctDNA), assays utilizing a standard blood sample, or liquid biopsy. The Company's Target-Selector offering is based on an internally developed, microfluidics-based CTC capture and analysis platform, with enabling features that change how CTC testing can be used by clinicians by providing biomarker detection and monitoring requiring only a standard blood sample. The ctDNA technology enables mutation detection and is applicable to nucleic acid from CTCs or other sample types, such as blood plasma. The Company commercializes its Target-Selector assays for a range of solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), gastric cancer, colorectal cancer, prostate cancer and melanoma.

SPONSORED STORIES